Modulatory Effects of Silymarin on Benzo[a]pyrene-Induced Hepatotoxicity.

Seung-Cheol Jee, Min Kim, Jung-Suk Sung
Author Information
  1. Seung-Cheol Jee: Department of Life Science, Dongguk University-Seoul, Biomedi Campus, 32 Dongguk-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do 10326, Korea.
  2. Min Kim: Department of Life Science, Dongguk University-Seoul, Biomedi Campus, 32 Dongguk-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do 10326, Korea.
  3. Jung-Suk Sung: Department of Life Science, Dongguk University-Seoul, Biomedi Campus, 32 Dongguk-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do 10326, Korea.

Abstract

Benzo[a]pyrene (B[a]P), a polycyclic aromatic hydrocarbon, is a group 1 carcinogen that introduces mutagenic DNA adducts into the genome. In this study, we investigated the molecular mechanisms underlying the involvement of silymarin in the reduction of DNA adduct formation by B[a]P-7,8-dihydrodiol-9,10-epoxide (BPDE), induced by B[a]P. B[a]P exhibited toxicity in HepG2 cells, whereas co-treatment of the cells with B[a]P and silymarin reduced the formation of BPDE-DNA adducts, thereby increasing cell viability. Determination of the level of major B[a]P metabolites in the treated cells showed that BPDE levels were reduced by silymarin. Nuclear factor erythroid 2-related factor 2 (Nrf2) and pregnane X receptor (PXR) were found to be involved in the activation of detoxifying genes against B[a]P-mediated toxicity. Silymarin did not increase the expression of these major transcription factors, but greatly facilitated their nuclear translocation. In this manner, treatment of HepG2 cells with silymarin modulated detoxification enzymes through NRF2 and PXR to eliminate B[a]P metabolites. Knockdown of Nrf2 abolished the preventive effect of silymarin on BPDE-DNA adduct formation, indicating that activation of the Nrf2 pathway plays a key role in preventing B[a]P-induced genotoxicity. Our results suggest that silymarin has anti-genotoxic effects, as it prevents BPDE-DNA adduct formation by modulating the Nrf2 and PXR signaling pathways.

Keywords

References

  1. Arch Toxicol. 2016 Nov;90(11):2563-2581 [PMID: 27600793]
  2. Environ Health Perspect. 2015 Apr;123(4):277-84 [PMID: 25494523]
  3. PLoS One. 2013 Nov 08;8(11):e78356 [PMID: 24260113]
  4. Mol Cell Biol. 2005 Jan;25(1):162-71 [PMID: 15601839]
  5. Toxicol Sci. 2008 Jul;104(1):67-73 [PMID: 18381355]
  6. Proc Natl Acad Sci U S A. 2017 Jun 6;114(23):6062-6067 [PMID: 28536195]
  7. Chemosphere. 2011 Sep;84(10):1452-60 [PMID: 21561639]
  8. Free Radic Res. 2004 Sep;38(9):995-1002 [PMID: 15621718]
  9. Chemosphere. 2007 Jul;68(8):1511-8 [PMID: 17481694]
  10. J Toxicol Environ Health A. 2007 Aug;70(15-16):1391-4 [PMID: 17654259]
  11. Biochim Biophys Acta. 2014 Jun;1840(6):1747-54 [PMID: 24380877]
  12. Int J Occup Environ Med. 2019 Jul;10(3):124-136 [PMID: 31325295]
  13. Int Immunopharmacol. 2015 Jan;24(1):1-6 [PMID: 25479723]
  14. Arch Toxicol. 2016 Jun;90(6):1449-58 [PMID: 26238291]
  15. J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Feb 15;863(1):141-9 [PMID: 18255360]
  16. PLoS One. 2012;7(7):e39006 [PMID: 22808024]
  17. Ecotoxicol Environ Saf. 2010 Oct;73(7):1565-73 [PMID: 20132985]
  18. Mutat Res. 2013 Apr 15;752(1-2):34-41 [PMID: 23370448]
  19. Mutat Res. 2015 Mar;773:1-8 [PMID: 25769181]
  20. Lancet Oncol. 2005 Dec;6(12):931-2 [PMID: 16353404]
  21. Curr Pharm Biotechnol. 2012 Jan;13(1):210-7 [PMID: 21466434]
  22. J Pharmacopuncture. 2014 Jun;17(2):7-17 [PMID: 25780694]
  23. Drug Metab Dispos. 2012 Jan;40(1):120-9 [PMID: 21956953]
  24. Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):2030-4 [PMID: 16103456]
  25. Annu Rev Pharmacol Toxicol. 2014;54:95-117 [PMID: 24050699]
  26. Cancer Res. 2002 Sep 15;62(18):5196-203 [PMID: 12234984]
  27. Environ Toxicol Pharmacol. 2016 Mar;42:92-8 [PMID: 26851374]
  28. Chem Biol Interact. 2014 Dec 5;224:36-41 [PMID: 25451572]
  29. Aquat Toxicol. 2011 Oct;105(3-4):688-97 [PMID: 21996255]
  30. Int J Mol Sci. 2019 Nov 06;20(22): [PMID: 31698770]
  31. Pharmacol Rep. 2020 Feb;72(1):199-207 [PMID: 32016841]
  32. Ecotoxicol Environ Saf. 2014 Aug;106:86-94 [PMID: 24836882]
  33. Genes Environ. 2017 Apr 10;39:14 [PMID: 28405246]
  34. Toxicol In Vitro. 2011 Apr;25(3):671-83 [PMID: 21256954]
  35. Chem Res Toxicol. 2002 Feb;15(2):170-9 [PMID: 11849043]
  36. Ecotoxicol Environ Saf. 2014 Sep;107:251-9 [PMID: 25011122]
  37. Int J Biochem Cell Biol. 2010 Feb;42(2):297-305 [PMID: 19931411]
  38. Biochem Biophys Res Commun. 2003 Oct 24;310(3):824-9 [PMID: 14550278]
  39. Cancer Res. 1988 Jun 1;48(11):2946-54 [PMID: 3284639]
  40. Trends Pharmacol Sci. 2006 Aug;27(8):438-46 [PMID: 16820223]
  41. Mol Cell Biol. 2002 May;22(9):2883-92 [PMID: 11940647]
  42. Food Chem Toxicol. 2012 Sep;50(9):3206-14 [PMID: 22709784]
  43. Mutagenesis. 2014 Nov;29(6):409-17 [PMID: 25245543]
  44. Int J Cancer. 2012 Dec 15;131(12):2733-53 [PMID: 22961407]
  45. FEBS J. 2019 Nov;286(21):4215-4231 [PMID: 31199573]
  46. Antioxid Redox Signal. 2018 Dec 10;29(17):1727-1745 [PMID: 28899199]
  47. Reprod Toxicol. 2015 Dec;58:24-32 [PMID: 26247513]
  48. Arch Toxicol. 2013 Feb;87(2):269-80 [PMID: 22899102]
  49. Indian J Biochem Biophys. 2006 Oct;43(5):306-11 [PMID: 17133738]
  50. Toxicol Ind Health. 2015 Jun;31(6):523-41 [PMID: 23406957]
  51. Environ Health Perspect. 2015 Mar;123(3):246-54 [PMID: 25325763]
  52. Environ Mol Mutagen. 2005 Mar-Apr;45(2-3):106-14 [PMID: 15688365]
  53. Arch Biochem Biophys. 2004 Mar 1;423(1):6-11 [PMID: 14989258]
  54. IARC Monogr Eval Carcinog Risks Hum. 2010;92:1-853 [PMID: 21141735]
  55. Trends Mol Med. 2016 Jul;22(7):578-593 [PMID: 27263465]
  56. Drug Metab Pharmacokinet. 2006 Dec;21(6):437-57 [PMID: 17220560]
  57. Pharmazie. 2014 Dec;69(12):894-7 [PMID: 25951662]
  58. Oncogene. 2003 Oct 20;22(47):7537-52 [PMID: 14576857]
  59. Dev Neurosci. 2016;38(2):150-62 [PMID: 27271523]
  60. Minerva Med. 2014 Dec;105(6 Suppl 2):1-8 [PMID: 26076375]
  61. Arch Pharm Res. 2005 Mar;28(3):249-68 [PMID: 15832810]
  62. Drug Metab Pharmacokinet. 2018 Aug;33(4):211-214 [PMID: 29921510]
  63. PLoS One. 2014 Mar 24;9(3):e92992 [PMID: 24664296]
  64. Ecotoxicol Environ Saf. 2012 Dec;86:79-85 [PMID: 23067546]
  65. Basic Clin Pharmacol Toxicol. 2007 Jun;100(6):414-9 [PMID: 17516996]
  66. Iran J Pharm Res. 2016 Winter;15(1):247-52 [PMID: 27610165]
  67. Mutat Res. 2008 Jul-Aug;659(1-2):31-9 [PMID: 18164232]
  68. Adv Exp Med Biol. 2016;929:25-44 [PMID: 27771919]
  69. Proc Natl Acad Sci U S A. 1994 Dec 20;91(26):13033-7 [PMID: 7809167]
  70. Tumour Biol. 2014 May;35(5):4929-35 [PMID: 24477577]

Grants

  1. 14162MFDS072/Ministry of Food and Drug Safety

MeSH Term

7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide
Benzo(a)pyrene
Chemical and Drug Induced Liver Injury
DNA Adducts
DNA Damage
Hep G2 Cells
Humans
Mutagens
Protective Agents
Signal Transduction
Silymarin

Chemicals

DNA Adducts
Mutagens
Protective Agents
Silymarin
benzo(a)pyrene-7,8-dihydrodiol-9,10-epoxide-DNA
Benzo(a)pyrene
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide

Word Cloud

Created with Highcharts 10.0.0silymarinB[a]PNrf2adductformationcellsBPDE-DNAPXRDNAadductsBPDEtoxicityHepG2reducedmajormetabolitesfactoractivationSilymarindetoxificationBenzo[a]pyrenepolycyclicaromatichydrocarbongroup1carcinogenintroducesmutagenicgenomestudyinvestigatedmolecularmechanismsunderlyinginvolvementreductionB[a]P-78-dihydrodiol-910-epoxideinducedexhibitedwhereasco-treatmenttherebyincreasingcellviabilityDeterminationleveltreatedshowedlevelsNuclearerythroid2-related2pregnaneXreceptorfoundinvolveddetoxifyinggenesB[a]P-mediatedincreaseexpressiontranscriptionfactorsgreatlyfacilitatednucleartranslocationmannertreatmentmodulatedenzymesNRF2eliminateKnockdownabolishedpreventiveeffectindicatingpathwayplayskeyrolepreventingB[a]P-inducedgenotoxicityresultssuggestanti-genotoxiceffectspreventsmodulatingsignalingpathwaysModulatoryEffectsBenzo[a]pyrene-InducedHepatotoxicitybenzo[a]pyrene

Similar Articles

Cited By